All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Management of apixaban anticoagulation in a patient requiring therapeutic plasma exchange: a case report and a literature review

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064165%3A_____%2F24%3A10484642" target="_blank" >RIV/00064165:_____/24:10484642 - isvavai.cz</a>

  • Alternative codes found

    RIV/00216208:11110/24:10484642

  • Result on the web

    <a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=7JKANYxaW~" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=7JKANYxaW~</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1691/ph.2024.4550" target="_blank" >10.1691/ph.2024.4550</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Management of apixaban anticoagulation in a patient requiring therapeutic plasma exchange: a case report and a literature review

  • Original language description

    Therapeutic plasma exchange (TPE) is used as an effective treatment modality for a variety of autoimmune disorders. Apart from its desired effect of removing pathological blood components, it also can remove coagulation factors and drugs. Currently, there is an insufficient amount of information regarding the use of direct oral anticoagulants in this setting. In this article, we present a case report of a patient with myasthenia gravis and chronic anticoagulation with apixaban who underwent a series of TPE while continuing apixaban treatment. We observed that only 10 % of daily dose was removed by the procedure and plasma levels of apixaban corresponded with expected range. TPE was not associated with shortened drug plasma half-life. We did not observe any significant alteration of apixaban pharmacokinetics during the period of TPE therapy, as well as no thrombotic or bleeding events. This case report supports the use of apixaban in patients treated by TPE, nevertheless, to firmly establish apixaban efficacy and safety profile in this clinical setting further research is needed.

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database

  • CEP classification

  • OECD FORD branch

    30104 - Pharmacology and pharmacy

Result continuities

  • Project

  • Continuities

    I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Others

  • Publication year

    2024

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    Die Pharmazie

  • ISSN

    0031-7144

  • e-ISSN

  • Volume of the periodical

    79

  • Issue of the periodical within the volume

    7-8

  • Country of publishing house

    DE - GERMANY

  • Number of pages

    4

  • Pages from-to

    159-162

  • UT code for WoS article

    001304779300004

  • EID of the result in the Scopus database

    2-s2.0-85201592043